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Objectives This study was undertaken to determine if ticagrelor augments adenosine-induced coronary blood flow and the
sensation of dyspnea in human subjects.
Background Ticagrelor is a P2Y12 receptor antagonist that showed superior clinical benefit versus clopidogrel in a phase III
trial (PLATO [Platelet Inhibition and Patient Outcomes]). Ticagrelor has been shown to inhibit cell uptake of
adenosine and enhance adenosine-mediated hyperemia responses in a dog model.
Methods In this double-blind, placebo-controlled study, 40 healthy male subjects were randomized to receive a single
dose of ticagrelor (180 mg) or placebo in a crossover fashion. Coronary blood flow velocity (CBFV) was measured
by using transthoracic Doppler echocardiography at rest after multiple stepwise adenosine infusions given be-
fore and after study drug, and again after the infusion of theophylline.
Results Ticagrelor significantly increased the area under the curve of CBFV versus the adenosine dose compared with
placebo (p  0.008). There was a significant correlation between ticagrelor plasma concentrations and in-
creases in the area under the curve (p  0.001). In both treatment groups, the adenosine-induced increase in
CBFV was significantly attenuated by theophylline, with no significant differences between subjects receiving
ticagrelor or placebo (p  0.39). Furthermore, ticagrelor significantly enhanced the sensation of dyspnea during
adenosine infusion, and the effects were diminished by theophylline.
Conclusions Ticagrelor enhanced adenosine-induced CBFV and the sensation of dyspnea in these healthy male subjects
via an adenosine-mediated mechanism. (Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in
Healthy Male Subjects; NCT01226602) (J Am Coll Cardiol 2013;61:723–7) © 2013 by the American College of
Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.11.032Ticagrelor, a novel, oral, direct-acting, reversibly binding
P2Y12 receptor antagonist, is approved for the treatment of
patients with acute coronary syndrome (1). In the PLATO
(Platelet Inhibition and Patient Outcomes) trial, ticagrelor
significantly reduced the incidence of myocardial infarction,
stroke, or death from vascular causes, compared with standard
treatment with clopidogrel (2). In the same study, dyspnea and
asymptomatic ventricular pauses were more common in pa-
tients receiving ticagrelor than in those receiving clopidogrel.
It has been shown that ticagrelor can inhibit adenosine
cell uptake, likely through inhibition of the equilibrative
nucleoside transporter 1 (3). Ticagrelor also significantly
and dose dependently augmented adenosine-mediated cor-
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2012, accepted November 12, 2012.onary blood flow increases in a dog model (3). These
findings could suggest increased local adenosine levels in
patients treated with ticagrelor because both dyspnea and
ventricular pauses are known effects of adenosine (4,5).
The goal of the current study was to determine if ticagrelor,
at a clinically relevant dose, can augment adenosine-induced
physiological responses, coronary blood flow velocity (CBFV),
and dyspnea in healthy human subjects.
Methods
The study was approved by the Regional Ethical Review
Board in Gothenburg, Sweden, and was conducted in
accordance with the Declaration of Helsinki. Data manage-
ment and monitoring were performed by Quintiles AB,
Uppsala, Sweden.
Study population. Forty healthy male subjects age 18 to 40
years with a body mass index of 18 to 30 kg/m2 and
weighing 50 to 100 kg provided written informed consent
before participating in the study.
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blind, placebo-controlled, crossover
study. After screening, subjects
were randomized to receive ti-
cagrelor (180 mg) or placebo. Af-
ter a washout period of 6 to 21
days, subjects received the alterna-
tive regimen (Fig. 1A). They un-
derwent an overnight fast and
were required to abstain from caf-
feine for 24 h before study drug
administration.
Subjects received multiple intravenous adenosine infusions
with the use of a stepwise dosing protocol: 0, 50, 80, 110, and
140 g/kg/min (Fig. 1B). Adenosine infusions were given
predose, repeated 2 h postdose, and again 10 min after a
20-min intravenous infusion of theophylline (5 mg/kg).
Assessments. CBFV. CBFV was measured in the left ante-
rior descending coronary artery (LAD) before and during
the different adenosine infusions (ITEM Development AB,
Stocksund, Sweden) by using a Siemens Acuson platform
equipped with a 4V1C transducer with 3.5 MHz color and
1.75 MHz spectral Doppler frequency (Acuson Sequoia
512, Siemens, Mountain View, California) (6). To ensure
CBFV was measured in the same LAD segment, trough
repeated measurements, the surface anatomic position, de-
gree of rotation of the transducer, and the LAD position
relative to the left ventricle were carefully documented at the
Abbreviations
and Acronyms
AUC  area under the
curve
CBFV  coronary blood
flow velocity
CI  confidence interval
CV%  coefficient of
variation
LAD  left anterior
descending coronary artery
Figure 1 Study Design and Procedure
(A) Study design and (B) the procedures performed at visits 1 and 2. IV  intravefirst visit. Cine loops and Doppler images were stored for
offline measurements by using Image Arena 2.9.1 (TomTec
Imaging Systems GmbH, Unterschleissheim, Germany).
Mean diastolic flow velocity was calculated by manually tracing
the diastolic flow velocity signal. Baseline CBFV values were
calculated by using the mean value of 3 representative heart
beats. The mean hyperemic CBFV for each adenosine dose
was calculated as the mean of the 3 highest CBFV values.
TICAGRELOR EXPOSURE. Plasma concentrations of ticagre-
lor and its main circulating metabolite, AR-C124910XX,
were measured in venous blood collected 2 h postdose. After
protein precipitation, plasma concentrations of ticagrelor
and AR-C124910XX were analyzed by using liquid chro-
matography mass spectrometry. The lower limits of quan-
tification for ticagrelor and AR-C124910XX were 5 and 2.5
ng/ml, respectively (7).
DYSPNEA. Subjects were trained to self-report the sensation
of dyspnea after each adenosine dose by using the Borg
scale; the scale is scored from 1 (no sensation of dyspnea) to
10 (maximum sensation of dyspnea).
Statistical analysis. All data were summarized by using
SAS version 8.02 and R version 2.13.0. The effect of
ticagrelor compared with placebo on the area under the
curve (AUC) of CBFV versus the adenosine dose (primary
endpoint) was estimated by using a mixed-model analysis of
variance. The model included the log AUC change with
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effects; and subject within sequence as a random effect.
We used mixed effects models similar to the aforementioned
model to assess the effect of theophylline on the AUC of
CBFV versus adenosine dose on ticagrelor and placebo (sec-
ondary endpoint), the differences in baseline blood flow (ab-
sence of adenosine) between ticagrelor and placebo before and
after infusion of theophylline (secondary endpoint), and the
effect of ticagrelor compared with placebo on the CBFV
response at individual adenosine doses (exploratory endpoint).
Interday and intraday coefficients of variation (CV%) and
SDs for the CBFV and Borg scale results were estimated by
using a mixed-model analysis of variance with variance
component estimations. Wilcoxon signed rank tests were
used for testing the difference in Borg scale responses.
Results
CBFV response. The interindividual (predose) variation
(CV%) for adenosine-induced CBFV-AUC was 0.268 and
the intraindividual between-day (predose) and within-day
(pre- vs. post-placebo) CV%s were 0.001 and 0.013, respec-
tively (Figs. 2A and 2B).
The adenosine-induced CBFV-AUC increased 15%
(95% confidence interval [CI]: 9 to 21) with ticagrelor versus
4% (95% CI: –1 to 10) for placebo (p  0.008) (Fig. 3A).
ssessing the effect of ticagrelor according to dose of adenosine,
here was a significant increase in CBFV when adenosine was
iven at 50 and 80 g/kg/min (95% CI: 0.1 to 10.0 and 6.7 to
29.1, respectively).
Theophylline infusion significantly reduced the adenosine-
induced CBFV-AUC in both study groups (point estimates
and 95% CIs: AUC-ticagrelor-theophylline/AUC-ticagrelor:
0.655 [0.612 to 0.702] vs. AUC-placebo-theophylline/AUC-
placebo: 0.628 [0.586 to 0.673]). The reduction was not
significantly different in subjects receiving ticagrelor or placebo
(point estimate and 95% CI: 1.04 [0.946 to 1.15]; p  0.39)
(Fig. 3B).
CBFV in the absence of adenosine was similar before and
after administration of ticagrelor (25.4  6.1 cm/s vs. 26.3 
7.0 cm/s) and placebo (25.6 6.3 cm/s vs. 24.9 5.5 cm/s)
and was not significantly attenuated by theophylline (25.4
6.1 cm/s vs. 22.0  5.5 cm/s and 25.6  6.3 cm/s vs. 21.4 
5.0 cm/s for ticagrelor and placebo, respectively).
There was a significant correlation between ticagrelor, but
not AR-C124910XX (data not shown), in terms of plasma
concentrations and change in adenosine-induced CBFV-
AUC (r  0.53; p  0.001) (Fig. 4).
Dyspnea. The interindividual (pre-dose) variation (SD) for
adenosine-induced dyspnea was 0.90, and the intraindi-
vidual variability (SDs) between days (pre-dose) and within
days (pre- vs. post-placebo) was 0.09 and 0.05, respectively.
Ticagrelor significantly augmented the adenosine-
induced dyspnea at adenosine doses of 110 and 140 g/kg/min
(p  0.05), whereas no difference was seen post-placebo
(Fig. 5A). Comparing the Borg scale findings between the wticagrelor and placebo groups, values were significantly
increased by ticagrelor at adenosine doses of 80, 110, and
140 g/kg/min (p  0.01).
Theophylline infusion significantly reduced the adenosine-
induced dyspnea in both treatment groups, at all adenosine
doses (except 50 g/kg/min for placebo; p  0.01) (Fig. 5B).
afety. An imbalance of episodes of second-degree atrioven-
ricular block was observed during adenosine infusion (ticagre-
or: 6; placebo: 3). However, there was a similar imbalance
uring adenosine infusion predose (4 vs. 2). Post-theophylline,
here was only 1 episode in the ticagrelor group versus none in
he placebo group. All occurrences of atrioventricular block
Figure 2 Variability and Reproducibility
of the CBFV Measurement
(A) Adenosine dose versus mean coronary blood flow velocity (CBFV) response
pre-placebo (red dashed line, red circle), post-placebo (red solid line, red trian-
gle), and pre-ticagrelor (blue dashed line, blue circle) and (B) the individual area
under the curve (AUC) of the CBFV versus adenosine dose pre-placebo and pre-ti-
cagrelor. Overlapping symbols have been slightly separated for visibility.ere of short duration and of no clinical significance.
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This study shows, for the first time, that ticagrelor augments
adenosine-induced physiological responses in human sub-
jects. Ticagrelor (180 mg) shifted the dose-response curve
for adenosine-induced CBFV to the left (Fig. 3A) and
significantly enhanced the AUC for CBFV response versus
adenosine dose compared with placebo. The increase in
AUC correlated with ticagrelor plasma concentrations.
However, no correlation was found for the metabolite
Figure 3 Treatment Effect on Adenosine-Induced CBFV
(A) Adenosine-induced mean coronary blood flow velocity (CBFV) and (B) mean
CBFV after theophylline. Symbols are given by pre-placebo (red dashed line, red
circle), post-placebo (red solid line, red triangle), pre-ticagrelor (blue dashed line,
blue circle), post-ticagrelor (blue solid line, blue triangle), post–theophylline-pla-
cebo (red dotted line, red diamond), and post–theophylline-ticagrelor (blue dotted
line, blue diamond). Overlapping symbols have been slightly separated for
visibility.AR-C124910XX (approximately equipotent with ticagreloron P2Y12), suggesting that the parent compound is mainly
driving the effect. The low interindividual and intraindi-
vidual variability over time for the CBFV response supports
the hypothesis that differences in CBFV were a result of
treatment effects and were not due to technical variability.
The enhanced vasodilation response to adenosine in the
presence of ticagrelor was mediated by adenosine receptors,
as demonstrated by a right shift of the adenosine dose-
response curve after infusion of theophylline, a nonselective
competitive adenosine receptor antagonist (Fig. 3B). The
magnitude of the right shift of the adenosine dose-response
curve induced by theophylline was similar for both placebo
and ticagrelor. Thus, this study demonstrates an adenosine-
related mode of action for ticagrelor in humans.
Ticagrelor, by preventing its cellular uptake, effectively
extends the half-life of adenosine and will thereby increase
extracellular levels of locally produced endogenous adeno-
sine. This action may be important in vessel damage or
hypoxia, where increased adenosine levels may contribute to
vasodilation. In addition to promoting myocardial perfu-
sion, there are additional adenosine-mediated cardioprotec-
tive effects that may be enhanced in patients treated with
ticagrelor, such as ischemic preconditioning, inhibition of
inflammatory response, and inhibition of platelet activation
(8,9). In clinical trials, adenosine infusion has been shown to
reduce myocardial infarct size but not major cardiovascular
events (10,11). A possible advantage for ticagrelor over aden-
osine infusion is the local enhancement of adenosine levels in
ischemic tissues (rather than a systemic effect).
Adenosine is known to induce dyspnea that is not
associated with bronchospasm (4). In addition to augmen-
tation of adenosine-induced CBFV, the current study dem-
Figure 4 Concentration-Dependent
Effect by Ticagrelor on CBFV
Correlation between individual plasma concentrations of ticagrelor and change
in the AUC for the adenosine-induced CBFV response. Abbreviations as in Figure 2.
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adenosine-induced dyspnea according to the Borg scale. As
with CBFV, the effect could be reversed by use of theoph-
ylline, an adenosine receptor antagonist. Thus, this study
demonstrated for the first time that ticagrelor, at similar
exposures as seen in the PLATO study (2), can augment
adenosine-mediated biological responses in humans.
Taken together, this adenosine-mediated secondary
mode of action of ticagrelor may provide a plausible mech-
Figure 5 Treatment Effect on Adenosine-Induced Dyspnea
(A) Adenosine-induced median Borg scale and (B) the effect of the adenosine
receptor antagonist theophylline. Symbols are given by pre-placebo (red dashed
line, red circle), post-placebo (red solid line, red triangle), pre-ticagrelor (blue
dashed line, blue circle), post-ticagrelor (blue solid line, blue triangle), post–the-
ophylline-placebo (red dotted line, red diamond), and post–theophylline-ticagrelor
(blue dotted line, blue diamond). Overlapping lines and symbols have been
slightly separated for visibility.anistic explanation for the cardioprotective effects, as well asthe increased occurrence of dyspnea, observed in patients
taking ticagrelor versus clopidogrel in the PLATO study
(12). Further clinical studies are warranted.
Conclusions
This study was performed in healthy male volunteers after a
single dose (180 mg) without co-medication and other con-
founding risk factors. The effects of exogenous (infused) rather
than local endogenous adenosine were studied. Caution should
be taken when extrapolating the findings to effects of chronic
treatment in patients with acute coronary syndrome who may
also have altered resting coronary blood flow dynamics due to
advanced coronary artery diseases.
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